United Therapeutics and Herbalife International Settle All Patent Litigation
SILVER SPRING, Md., Nov. 13 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that its wholly owned subsidiary Unither Pharma, Inc. has settled all patent litigation with Herbalife International, Inc. ("Herbalife"). The patent litigation, which began in August 2003, related to products sold by Herbalife containing the amino acid L-arginine and Herbalife's promotion of such products to support cardiovascular and vascular function.
United Therapeutics is the exclusive licensee of five patents licensed to it by Stanford University and New York Medical College with claims relating to L- arginine and vascular function, in particular L-arginine's role in the cardiovascular system's nitric oxide pathway.
Under the terms of the settlement arrangement, all pending lawsuits will be dismissed with Herbalife, and Herbalife has entered into a royalty-bearing, non- exclusive license under United Therapeutics' patents. Financial terms of the settlement were not disclosed.
About United Therapeutics
United Therapeutics is a biotechnology company focused on the development and commercialization of unique products for patients with chronic and life- threatening cardiovascular, cancer and infectious diseases.
About Herbalife
Herbalife is a global network marketing company that sells weight- management, nutritional supplements and personal care products intended to support a healthy lifestyle. Herbalife products are sold in 62 countries through a network of more than one million independent distributors. The company supports the Herbalife Family Foundation and its Casa Herbalife program to bring good nutrition to children. Please visit Herbalife.com for additional information.
SOURCE
Contact: Andrew Fisher of United Therapeutics, +1-301-608-9292, [email protected]; or George Fischer of Herbalife, +1-310-410-9600, [email protected]